Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.2K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.2K
Cross-bridge Cycle01:26

Cross-bridge Cycle

108.8K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
108.8K
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

29
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
29
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

1.7K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.7K
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

53
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
53
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gross motor delays in infants and young boys with Duchenne muscular dystrophy.

Journal of neuromuscular diseases·2025
Same author

Transitioning From Nusinersen to Risdiplam for Spinal Muscular Atrophy in Clinical Practice: A Single-Center Experience.

Muscle & nerve·2025
Same author

Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio.

Neuromuscular disorders : NMD·2023
Same author

Pathogenic missense variants altering codon 336 of GARS1 lead to divergent dominant phenotypes.

Human mutation·2022
Same author

Validity and Reliability of the Neuromuscular Gross Motor Outcome.

Pediatric neurology·2021
Same author

Natural History of Steroid-Treated Young Boys With Duchenne Muscular Dystrophy Using the NSAA, 100m, and Timed Functional Tests.

Pediatric neurology·2020

Related Experiment Video

Updated: May 3, 2026

Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

8.5K

Muscle disease.

Chang-Yong Tsao1

  • 1Department of Clinical Pediatrics and Neurology, College of Medicine, The Ohio State University, Columbus, OH.

Pediatrics in Review
|February 4, 2014
PubMed
Summary
This summary is machine-generated.

Duchenne muscular dystrophy (DMD) is a severe childhood genetic disorder causing progressive muscle weakness. Early treatment with corticosteroids and heart medications can help manage symptoms and improve quality of life.

More Related Videos

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease
09:30

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease

Published on: December 18, 2016

18.6K
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

56.9K

Related Experiment Videos

Last Updated: May 3, 2026

Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

8.5K
Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease
09:30

Quantitative Magnetic Resonance Imaging of Skeletal Muscle Disease

Published on: December 18, 2016

18.6K
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

56.9K

Area of Science:

  • Genetics and Molecular Biology
  • Pediatric Neurology
  • Cardiology

Background:

  • Duchenne muscular dystrophy (DMD) is the most common severe childhood muscular dystrophy, an X-linked recessive disorder.
  • It results from out-of-frame mutations in the dystrophin gene, classifying it as a dystrophinopathy.
  • Disease onset occurs before age five, leading to progressive muscle weakness.

Observation:

  • Patients typically become wheelchair-dependent after age 12.
  • Cardiomyopathy and heart failure emerge in late teens.
  • Scoliosis and respiratory insufficiency develop with wheelchair dependency, and respiratory failure/cardiomyopathy are leading causes of death.

Findings:

  • Corticosteroids like prednisone or deflazacort are recommended for DMD patients over five, potentially prolonging independent walking by months to two years.
  • Angiotensin-converting enzyme inhibitors, beta-blockers, and diuretics show benefit for cardiac issues in DMD.
  • Elevated serum creatine kinase levels in children with muscle weakness may indicate genetic or acquired muscle disorders.

Implications:

  • Early intervention with corticosteroids and cardiac medications can significantly impact the management of Duchenne muscular dystrophy.
  • Understanding the genetic basis and progressive nature of DMD is crucial for developing targeted therapies.
  • Further research into dystrophinopathies can lead to improved patient outcomes and longevity.